Rhythm Pharmaceuticals Appoints Kim Popovits To Board As Ed Mathers Steps Down After Years Of Leadership

Rhythm Pharmaceuticals, Inc., a global commercial-stage biopharmaceutical company dedicated to improving the lives of people with rare neuroendocrine diseases, announced updates to its Board of Directors. The company has appointed Kim Popovits as a new board member, while Ed Mathers will be departing from the Board.

David Meeker, M.D., who is the Chairman, President and Chief Executive Officer of Rhythm, said the company is pleased to have Kim join its Board of Directors. He explained that she brings many years of leadership experience in biotechnology, diagnostics and commercial innovation. 

Her background includes building strong organizations and helping deliver important medical products to patients. Dr. Meeker added that her expertise in commercialization, reimbursement and corporate governance will play an important role as Rhythm works toward its long-term goals and mission.

Dr. Meeker also expressed appreciation for Ed Mathers and his contributions to the company. Ed has served on Rhythm’s Board since 2013, offering deep biopharmaceutical industry knowledge and a long-term strategic perspective. His guidance and steady leadership have supported the company’s development and progress over the years.

Kim Popovits has more than four decades of experience in the life sciences industry and has been part of several innovative healthcare companies. She previously served as Chairman of the Board, Chief Executive Officer and President of Genomic Health, where she led the development and commercialization of the Oncotype DX test. 

Earlier in her career, she held senior leadership positions at Genentech, where she contributed to the commercialization of several first-in-class therapies. She also worked at American Critical Care, which is a division of American Hospital Supply Corporation. Currently, she serves on the boards of multiple public and private life sciences companies and is an Executive Advisor to Blackstone Life Sciences.